Together, these results demonstrate the reciprocal activation loop of PI3K-AKT-mTOR and β1 signalling, a central signalling hub for IR, resulting in enforced TME–lymphoma interactions and promoting MCL growth and drug resistance. The gene discussed is AKT1; the disease is lymphoma.